Early trials show promise for Sinovac vaccine, East Asia News & Top Stories

Henrietta Brewer
November 22, 2020

Phase 3 trials are now underway to determine the vaccine's effectiveness against the disease.

The Sinovac tests were done in the early days of the pandemic, in April and May, with later-stage efforts now ongoing; the trial was also assessing what dose to use in these tests, with the biotech finding the 3-μg dose of CoronaVac would be used for phase 3 studies.

And, crucially, the researchers wanted to know if it might work in older people who are most at risk of severe Covid.

Vials of the Oxford coronavirus vaccine
Vials of the Oxford coronavirus vaccine

Commenting on the findings, Zhu Fengcai, one of the authors of the paper, said: "Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval.

We and it's not a competition with the other developers", Oxford's Professor Pollard said, adding that AstraZeneca would release headline efficacy data before it was published in an academic journal.

Mr Hahn said the agency has been preparing for the review of emergency use authorisation for Covid-19 vaccines for several months and stands ready to do so as soon as a request is submitted.

Sinovac is now running three phase three trials - in Indonesia, Brazil and Turkey.

Dr. Andrew Pollard leads the University of Oxford study. "But even then, after phase three trial completion and after licensure, we should prudently remain cautious", he said. Like with other kinds of vaccines, mass producing them for the coronavirus has proved to be a complex and delicate process requiring sterile conditions and precise control of temperature and humidity.

The one where they looked for any adverse safety issues in more than 500 people. "(It) would offer some advantages for distribution to regions where access to refrigeration is challenging", he said.

Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA (mRNA), AstraZeneca's is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees.

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose. Moderna's vaccine can last for a month in a normal fridge or six months if stored at minus 20 Celsius.

This is the first coronavirus vaccine to seek a regulatory OK in the United States.

Other reports by iNewsToday